IDIOPATHIC PULMONARY FIBROSIS

This study tested a new oral medication called TTI-101 in 100 people with idiopathic pulmonary fibrosis (IPF), a serious lung scarring disease. The main goal was to see if taking the pill daily for 12 weeks was safe and how the body handled the drug. The study also looked for ear…

This was the first study in humans to test the safety of an experimental drug called HuL001 for idiopathic pulmonary fibrosis (IPF), a serious disease that causes permanent lung scarring. The study first gave single doses to 12 healthy volunteers to check for side effects, then g…

This study tested whether a new drug called PLN-74809 could reduce the buildup of scar tissue in the lungs of people with idiopathic pulmonary fibrosis (IPF). Ten participants took either the drug or a placebo pill daily for 12 weeks. Researchers used special PET/MRI scans to mea…

This study tested the safety and effects of an inhaled drug called ARO-MMP7 in healthy volunteers and people with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. The goal was to see if the drug was safe and how it behaved in the body. The study involved 105 …

This early-stage study tested the safety and how the body processes a new oral medication called BI 1015550 in people with idiopathic pulmonary fibrosis (IPF). It involved 15 patients who were not taking other standard IPF medications. The main goal was to see what side effects o…

This study tested whether a daily oral pill called GRI-0621 is safe and can affect markers of disease in people with IPF, a condition that causes progressive lung scarring. About 35 participants took either the study drug or a placebo pill for 12 weeks. The main goal was to check…

This small, early-stage study tested whether an injection of stem cells taken from human umbilical cords is safe and tolerable for people with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. The main goal was to find a safe dose by carefully monitoring 17 pa…

This large, completed Phase 3 trial tested whether a new oral medicine called BI 1015550 could help adults with Idiopathic Pulmonary Fibrosis (IPF), a serious lung-scarring disease. Over 1,100 participants, some already on standard IPF drugs, were randomly assigned to take either…

This study tested whether an inhaled medication called treprostinil could help slow the decline of lung function in people with idiopathic pulmonary fibrosis (IPF), a serious scarring lung disease. About 600 participants were randomly assigned to receive either the active drug or…

This study tested whether an oral drug called MN-001 could help control idiopathic pulmonary fibrosis (IPF), a serious disease that scars the lungs. Fifteen adults with moderate to severe IPF took either MN-001 or a placebo pill twice daily for six months, followed by another six…

This study tested whether a new oral medicine called BI 1819479 could help slow the progression of idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. Over 300 adults with IPF took either one of three different doses of the medicine or a placebo pill for 6 to 12…

This study tested whether a new cell therapy called REGEND001 could help people with idiopathic pulmonary fibrosis (IPF), a serious disease that scars the lungs. In this Phase 2 trial, 23 patients were randomly assigned to receive either the cell therapy or a placebo (dummy treat…

This study tested whether a drug called orvepitant could reduce the severity and frequency of chronic cough in people with idiopathic pulmonary fibrosis (IPF), a serious scarring lung disease. In this completed Phase 2 trial, 80 participants tried both the study drug and a placeb…

This study observed 178 patients with advanced cancer, lung disease, or kidney failure to understand when and how palliative care (comfort-focused treatment) should be provided alongside regular medical care. Researchers tracked patients' standard treatment without changing it, a…

This small study tested whether a vibrating breathing device could help inhaled medicine reach the scarred parts of the lungs in people with idiopathic pulmonary fibrosis (IPF). Nine patients inhaled a safe, traceable mist with and without the device to see where it landed. The m…